N-Power Lands $32M to Scale Oncology Trial Network

N-Power Medicine has secured a significant $32 million investment in its Series B round to scale up its community oncology network and develop new drug products.

The funding, which comes from strategic investor Labcorp Venture Fund alongside continued backing from Merck Global Health Innovation Fund and others, will enable N-Power to expand its national network of community oncology centers built around its Prospective External Control Arm (ProECA) product.

ProECAs are trial-grade external control arms generated in routine care, cutting the patient enrollment, timelines, and costs of clinical trials while reducing reliance on randomization.